Subscribe To
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD). CT1812 is an experimental orally delivered, small molecule drug candidate that binds to σ-2 receptors, which […] The post Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macu...
Read More
Content Topics
Cognition
Therapeutics
Present
Analysis
Showing
Impact
Ct1812
Pathways
Implicated
Age related
Macular
Degeneration
Forex
Posted: Apr 19 2023, 11:30
Author Name: forextv
Views: 102083